Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $686.4 million.

  • Arrowhead Pharmaceuticals' Total Non-Current Liabilities fell 18.83% to $686.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $686.4 million, marking a year-over-year decrease of 18.83%. This contributed to the annual value of $686.4 million for FY2025, which is 18.83% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $686.4 million for FY2025, which was down 18.83% from $845.6 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Total Non-Current Liabilities peaked at $845.6 million during FY2024, and registered a low of $134.8 million during FY2022.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $686.4 million (2025), whereas its average is $635.0 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 672.29% in 2021 and then fell by 18.83% in 2025.
  • Arrowhead Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $154.8 million in 2021, then fell by 12.95% to $134.8 million in 2022, then skyrocketed by 176.76% to $372.9 million in 2023, then soared by 126.73% to $845.6 million in 2024, then declined by 18.83% to $686.4 million in 2025.